<DOC>
	<DOCNO>NCT01999218</DOCNO>
	<brief_summary>This study evaluate efficacy safety addition ertugliflozin ( MK-8835/PF-04971729 ) compare addition glimepiride participant T2DM inadequate glycemic control metformin . The duration trial approximately 122 week . This include 1-week screening period , 13-week wash-off/titration/dose stabilization period , 2-week placebo run-in period , 104-week double-blind , active comparator-controlled treatment period , post-treatment telephone contact 14 day last dose study drug . The primary hypothesis study 52 week , change baseline hemoglobin A1c ( A1C ) participant treat addition ertugliflozin 15 mg daily non-inferior compare participant treat addition glimepiride .</brief_summary>
	<brief_title>Ertugliflozin vs. Glimepiride Type 2 Diabetes Mellitus ( T2DM ) Participants Metformin ( MK-8835-002 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosis T2DM accordance American Diabetes Association guideline On metformin monotherapy metformin combination single allowable antihyperglycemic agent ( AHA ) , DPP4 inhibitor , meglitinides AGIs list allowable AHAs along sulfonylureas prior study participation . Body Mass Index ( BMI ) ≥18.0 kg/m^2 Male female reproductive potential If female reproductive potential , agree remain abstinent use ( partner use ) 2 acceptable combination birth control participate trial 14 day last use study drug . History presence type 1 diabetes mellitus history ketoacidosis History specific type diabetes ( eg , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrinopathies , drug chemicalinduced , postorgan transplant ) . A known hypersensitivity intolerance sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor Use follow prohibit therapeutic agent within 12 week study participation : insulin , injectable antihyperglycemic agent , pioglitazone rosiglitazone , another SGLT2 inhibitor , bromocriptine ( Cycloset® ) , colesevelam ( Welchol® ) , nonapproved antihyperglycemic therapy Known hypersensitivity intolerance metformin glimepiride On weightloss program medication medication associate weight change weightstable ( &gt; =5 % change body weight last 6 month ) History bariatric surgery le 12 month prior study participation History myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study participation Active , obstructive uropathy indwell urinary catheter A history malignancy ≤5 year prior study participation , except adequately treat basal squamous cell skin cancer situ cervical cancer Known history Human Immunodeficiency Virus ( HIV ) Blood dyscrasia disorder cause hemolysis unstable red blood cell A medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C ( assessed medical history ) , primary biliary cirrhosis , symptomatic gallbladder disease Any clinically significant malabsorption condition Being treat hyperthyroidism , thyroid replacement therapy stable dose least 6 week prior study participation Previous randomization study ertugliflozin Participation study involve investigational drug ( ) within 30 day study participation and/or prerandomization period A surgical procedure within 6 week prior study participation plan major surgery trial A positive urine pregnancy test Pregnant breastfeeding , expect conceive trial , include 14 day follow last dose study drug Undergoing hormonal therapy preparation donate egg period trial , include 14 day follow last dose study drug Consumption 2 alcoholic drink per day engage binge drink Donation blood blood product within 6 week study participation plan donate blood blood product time trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>